about
Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry.Macrophage activation syndrome in juvenile systemic lupus erythematosus: a multinational multicenter study of thirty-eight patients.EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part I: Overall methodology and clinical characterisation.Elicitation of expert prior opinion: application to the MYPAN trial in childhood polyarteritis nodosa.A Heterozygous RAB27A Mutation Associated with Delayed Cytolytic Granule Polarization and Hemophagocytic Lymphohistiocytosis.Macrophage Activation Syndrome: different mechanisms leading to a one clinical syndrome.Herpes Virus Infections During Treatment With Etanercept in Juvenile Idiopathic Arthritis.Necrotizing fasciitis in a pediatric patient treated with etanercept and cyclosporine for macrophage activation syndrome.Safety and efficacy of etanercept in a cohort of patients with juvenile idiopathic arthritis under 4 years of age.Necrosis of the tongue as first symptom of Polyarteritis Nodosa (PAN): unusual presentation of a rare disease in children.Prognostic impact of atypical presentation in pediatric systemic lupus erythematosus: results from a multicenter study.Cronic non-bacterial osteomyelitis (CNO) in a cohort of pediatric patients: clinical, biological and radiological response to treatment with Anakinra.S100A12 as diagnostic tool in the differential diagnosis of sJIA associated MAS vs. hereditary or acquired HLH.High levels of interferon-gamma (IFNγ) in macrophage activation syndrome (MAS) and CXCL9 levels as a biomarker for IFNγ production in MAS.Neutralization of IFN-γ reverts clinical and laboratory features in a mouse model of macrophage activation syndrome.Longitudinal myelitis in systemic lupus erythematosus: a paediatric case.Elevated circulating levels of interferon-γ and interferon-γ-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.Longterm Safety and Efficacy of Adalimumab and Infliximab for Uveitis Associated with Juvenile Idiopathic Arthritis.MRI assessment of bone marrow in children with juvenile idiopathic arthritis: intra- and inter-observer variability.Anti interferon-gamma (IFNγ) monoclonal antibody treatment in a patient carrying an NLRC4 mutation and severe hemophagocytic lymphohistiocytosis.Neutralization of Interferon-gamma is efficacious in a mouse model of HLH secondary to chronic inflammation.Drug Retention Rate and Predictive Factors of Drug Survival for Interleukin-1 Inhibitors in Systemic Juvenile Idiopathic ArthritisAnakinra in Systemic Juvenile Idiopathic Arthritis: A Single-center ExperienceInhibition of Natural Killer Cell Cytotoxicity by Interleukin-6: Implications for the Pathogenesis of Macrophage Activation SyndromeMRI of the wrist in juvenile idiopathic arthritis: proposal of a paediatric synovitis score by a consensus of an international working group. Results of a multicentre reliability studyInfliximab therapy in pediatric Takayasu’s arteritis: report of two casesAn unusual presentation of purine nucleoside phosphorylase deficiency mimicking systemic juvenile idiopathic arthritis complicated by macrophage activation syndromeSystemic juvenile idiopathic arthritis: New insights into pathogenesis and cytokine directed therapiesA novel disorder involving dyshematopoiesis, inflammation, and HLH due to aberrant CDC42 functionVariable Clinical Phenotypes and Relation of Interferon Signature with Disease Activity in ADA2 DeficiencyThe interferon-gamma pathway is selectively up-regulated in the liver of patients with secondary hemophagocytic lymphohistiocytosisInterleukin-18 in pediatric rheumatic diseases
P50
Q30575712-79CDD109-8100-460F-9B9E-5779D1005190Q33386883-59DD9453-3D13-4188-83AD-D04643B36649Q34109962-ECBC258C-32AD-46E6-8A1A-68BE99DC653BQ35590334-4DB5B5C4-31EB-40AE-A381-4BE4DDD27647Q36655896-F669D2AE-BC2E-4307-824E-46FC968AAC0AQ37589316-699FE684-2488-4185-9199-C8078D66F9B4Q40780138-FEC78B7C-F694-4E9F-8654-8F27AB57E4CCQ43630443-8CEF2207-70C9-4378-B953-BC207C562E2DQ43858787-A7F08C39-BEE7-4B97-929B-CC911602F4BEQ43972564-5629E1BD-C4A4-4B61-AD07-E02C262349EAQ44216791-2A906A72-BEAF-4337-804F-979548774933Q46286222-181E3D3D-65FE-4E57-9653-DA2F51DFC327Q46449351-BD8729FD-D8FB-4B27-9BB7-FA212649F4DFQ46591463-072521AA-DBC0-4744-8007-AA758565D3BEQ50503576-183C479E-92A0-427E-9F6F-F75C91C5466EQ51434399-A5D9740A-7AB7-4968-A870-3BAAE1B811CBQ51705351-BF6E5C66-9DA8-4AAD-AFE3-81FF85A45500Q52587399-E6459B75-32E6-4E62-8C55-F02B314D538AQ53097298-ACD44195-E385-4CF8-8545-0C867E56E167Q54899649-83687DD7-CD13-4F23-A3B0-FF6EF8EC78B1Q55058860-A24C0322-89B5-46DD-B7E0-3431A7C753EDQ60916566-28D4FF69-B92E-4D00-BAF2-4121C118D381Q61911597-F1132C08-97E6-48E9-A18D-073A16017391Q61911602-2985EB26-B762-4A04-B138-1841789C1BE8Q61911620-61582AED-DFB4-4623-BB3B-89C88CDAC8A9Q61911623-0C95BF0C-8D78-475D-8885-F324DC2D7257Q64279069-821ADF81-5993-4EE7-84B2-325695464A16Q88719899-E168BE74-1CAB-4E0B-AF9C-5B49A23F8AB5Q90638441-61323672-8660-41F8-AA59-571836206D8AQ91062298-093D1706-FAE4-4764-B906-EEEDCE0A864CQ92043407-56E99BD9-4C7F-4B2B-AF60-DC5A42283F92Q92708063-49401F4B-2E23-4709-B1E4-18431A9619B9
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Claudia Bracaglia
@ast
Claudia Bracaglia
@en
Claudia Bracaglia
@es
Claudia Bracaglia
@nl
Claudia Bracaglia
@sl
type
label
Claudia Bracaglia
@ast
Claudia Bracaglia
@en
Claudia Bracaglia
@es
Claudia Bracaglia
@nl
Claudia Bracaglia
@sl
prefLabel
Claudia Bracaglia
@ast
Claudia Bracaglia
@en
Claudia Bracaglia
@es
Claudia Bracaglia
@nl
Claudia Bracaglia
@sl
P106
P1153
26641790500
P21
P31
P496
0000-0002-9834-9619